Nano-X Imaging remains a 'sell' due to weak revenue growth, worsening losses, and limited traction in its core business. NNOX's advanced imaging technology and AI offerings have yet to translate into significant sales, with most revenue still from teleradiology services. Recent partnerships and acquisitions, including VasoHealthcare IT and European distribution deals, offer potential but lack a clear financial impact.
Nano-X Imaging Ltd. ( NNOX ) Q3 2025 Earnings Call November 20, 2025 8:30 AM EST Company Participants Mike Cavanaugh - IR-ICR Westwicke Erez Meltzer - CEO & Acting Chairman of the Board Ran Daniel - Chief Financial Officer Conference Call Participants Ross Osborn - Cantor Fitzgerald & Co., Research Division Jeffrey Cohen - Ladenburg Thalmann & Co. Inc., Research Division Scott Henry - Alliance Global Partners, Research Division Presentation Operator Good day, and thank you for standing by.
Nano-X Imaging Ltd.'s Q2 results missed expectations, with revenue, EPS, and adjusted EPS all falling short and losses widening year-over-year. Despite regulatory progress and some revenue growth, core fundamentals remain weak, and cash burn is unsustainable without further dilution or new capital. Management's limited guidance and unchanged unit growth outlook highlight ongoing operational and macroeconomic challenges, making near-term improvement unlikely.
Nano-X Imaging Ltd. (NASDAQ:NNOX ) Q2 2025 Earnings Conference Call August 12, 2025 8:30 AM ET Company Participants Erez I.
Nano-X Imaging Ltd. (NASDAQ:NNOX ) Q1 2025 Earnings Conference Call May 22, 2025 8:30 PM ET Company Participants Mike Cavanaugh - Investor Relations Erez Meltzer - Chief Executive Officer and Acting Chairman Ran Daniel - Chief Financial Officer Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann Ross Osborn - Cantor Fitzgerald Scott Henry - Alliance Global Partners Operator Good day, and thank you for standing by.
On Monday, many investors drew an X next to the name of Nano-X Imaging (NNOX -4.59%), also known as Nanox. The next-generation medical imaging specialist experienced a sell-off following its latest earnings release that morning, and by the end of the day, its price had fallen by almost 5%.
Nano-X Imaging Ltd. (NASDAQ:NNOX ) Q4 2024 Earnings Conference Call March 31, 2025 8:30 AM ET Company Participants Mike Cavanaugh - Investor Relations Erez Meltzer - Chief Executive Officer and Acting Chairman Ran Daniel - Chief Financial Officer Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann Ross Osborn - Cantor Fitzgerald Scott Henry - Alliance Global Partners Jason Colbert - DeBoro Capital Operator Good day and thank you for standing by.
Nvidia (NASDAQ:NVDA) shocked the market last month by disclosing it had dumped all of its shares in artificial intelligence voice recognition expert SoundHound AI ( NASDAQ:SOUN ), Serve Robotics (NASDAQ:SERV), and Nano X Imaging (NASDAQ:NNOX).
Shares of several artificial intelligence (AI) stocks in various sectors are getting crushed this morning after the AI chip king Nvidia revealed in documents filed with the Securities and Exchange Commission (SEC) that it exited its position in these companies.
Nano-X Imaging is my speculative play for disruptive innovation in the biotech sector. With the S&P 500 at historical highs, lagging sectors like healthcare seem relatively attractive. The biotech sector's large market size and potential make it an intriguing investment opportunity. The AI push in health sector is a long-term tailwind. NNOX is positioned well in offering real value from the AI system.
Here is how Nano-X Imaging Ltd. (NNOX) and VerifyMe, Inc. (VRME) have performed compared to their sector so far this year.
Shares of medical imaging company Nano-X Imaging (NNOX 3.02%) -- commonly referred to as Nanox -- went up on Thursday after some pretty substantial news broke regarding regulatory clearance. At 10:50 a.m.